About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The Microbiology research group of the Vall d'Hebron Research Institute (VHIR) focuses on the study of microbiological aspects —in basic, translational and clinical research— that could improve the outcome of patients with infectious diseases.
Our priority research areas are:
We actively collaborate with other microbiology laboratories, health services, national and international centres and organizations, as well as with the different research networks of the Carlos III Health Institute in Spain.
In addition, we carry out an important activity in the surveillance of the genotypic and phenotypic evolution of microorganisms present in the community in terms of their virulence, transmissibility, antigenic escape and antimicrobial resistance, in collaboration with public administrations, both at the national and international level.
IP: Juan Jose Gonzalez Lopez Collaborators: Caracterización de Neisseria meningitidis tras la introducción de la vacuna frente al serogrupo B e identificación de factores p, Josep Roca Grande Funding agency: Instituto de Salud Carlos III Funding: 60000 Reference: INT22/00083 Duration: 01/01/2023 - 31/12/2024
IP: Juan Jose Gonzalez Lopez Collaborators: María Nieves Larrosa Escartin, Maria Belén Viñado Perez, Alba Mir Cros, Albert Moreno Mingorance Funding agency: Fundació Institut Bioenginyeria de Catalunya Funding: 0.01 Reference: D7357 Duration: 02/01/2023 - 31/12/2024
IP: - Collaborators: José Antonio Arranz Amo, Raquel Barquin Del Pino, Laura Conesa Milian, Clara Ramírez Serra, Yolanda Villena Ortiz, Joan López Hellin, Albert Blanco Grau, Roser Ferrer Costa, Joaquin Seras Franzoso, Diego Baranda Martínez-Abasca, Laura Castillo Ribelles, Clara Carnicer Cáceres, Marina Giralt Arnaiz, Ana Gomez Garcia, Simon Schwartz Navarro, Pablo Gabriel Medina, Bioquímica Clínica, Vehiculització de Fàrmacs i Teràpia (Clinical Biochemistry, Drug Delivery & Therapy, CB-DDT), Bioquímica Clínica, Vehiculització de Fàrmacs i Teràpia (Clinical Biochemistry, Drug Delivery & Therapy, CB-DDT), Laura Castellote Bellés, Daniel Bravo Nieto, Luz María Cruz Carlos, Clara Sanz Gea, Alba Estela García Fernández, Maria del Pilar Reimundo Diaz-Fierros, Belen Garcia Prats, Noelia Díaz Troyano, JAUME VIMA BOFARULL, Bioquímica Clínica, Vehiculització de Fàrmacs i Teràpia (Clinical Biochemistry, Drug Delivery & Therapy, CB-DDT), Diana Fernandes de Rafael, Maria Francesca Cortese , Sandra Mancilla Zamora Funding agency: Agència Gestió Ajuts Universitaris i de Recerca Funding: 60000 Reference: 2021 SGR 01173 Duration: 01/01/2022 - 30/06/2025
IP: Eva Baldrich Rubio Collaborators: Judit Prat Trunas, Cristina Andrés Vergés, Briza Pérez López Funding agency: Agència Gestió Ajuts Universitaris i de Recerca Funding: 0.01 Reference: 2021 SGR 00617 Duration: 01/01/2022 - 30/06/2025
The technology could help make stool sample screening more comprehensive and facilitate the identification of parasitic findings for subsequent expert review.
The initiative focuses on awareness, prevention, and the normalization of sexual health check-ups among young people.
All patients showed a favorable clinical course and responded well to antibiotic treatment, without complications.
